

Regimen list

Regimen	Status
5-Fluorouracil (4 day) and mitoMYcin Chemoradiation - Version 2	Inactive
5-Fluorouracil (5 day) and mitoMYcin Chemoradiation - Version 2	Inactive
5-fluorouracil 225mg/m ² /day and Radiotherapy (RT)-Continuous infusion (7 day) - Version 4	Active
5-Fluorouracil, epiRUBicin 100 and Cyclophosphamide (FEC 100) - Version 1	Inactive
5-Fluorouracil, epiRUBicin 50 and Cyclophosphamide (FEC 50) Therapy - Version 2	Inactive
Abiraterone 1000mg and Prednisolone 5mg - Version 1	Inactive
Abiraterone and Prednisolone - Version 3	Inactive
ABVD - Version 3	Active
Afatinib Monotherapy - Version 1	Inactive
Aflibercept and FOLFIRI -14 day - Version 1	Inactive
Anastrozole Monotherapy Adj - Version 3	Active
Anastrozole Monotherapy LA/M - Version 2	Active
Axitinib Monotherapy - Version 1	Active
azaCITIDine 100mg/m ² 5-day - Version 2	Active
Azacitidine 75mg/m ² 5-2-2 - Version 2	Active
Bendamustine Monotherapy - Version 1	Inactive
Bevacizumab 10mg/kg - 14 days - Version 1	Inactive
Bevacizumab 15mg/kg - 21 days - Version 1	Inactive
Bevacizumab 5mg/kg -14 days - Version 2	Inactive
Bevacizumab 5mg/kg and FOLFIRI – 14 days - Version 1	Inactive
Bevacizumab 5mg/kg and Modified FOLFOX- 6 – 14 days - Version 1	Inactive
Bevacizumab 7.5mg/kg – 21 days - Version 1	Inactive
Bicalutamide - Version 1	Inactive
Bleomycin, Etoposide and CISplatin (BEP) - Version 1	Inactive
Bortezomib and Dexamethasone - Version 2	Active
Bortezomib Maintenance - 14 day - Version 2	Active
Bortezomib, Lenalidomide and Dexamethasone (RVD) - 21 day - Version 1	Active
Bortezomib, Melphalan & Prednisolone - Version 1	Active
Bortezomib, Thalidomide and Dexamethasone (VTD) Induction - Version 1	Active
Bosutinib Monotherapy - Version 1	Active
Brentuximab vedotin and Bendamustine - Version 1	Active
Brentuximab vedotin and ESHAP (BRESHAP) - Version 1	Inactive
Brentuximab vedotin Monotherapy - Version 1	Active
Brigatinib - Version 2	Inactive
Cabazitaxel and Prednisolone - Version 1	Active
Capecitabine 825mg/m ² and RT-7 day - Version 1	Inactive
Capecitabine and Oxaliplatin Therapy (XELOX) Adj - Version 2	Inactive
Capecitabine and Oxaliplatin Therapy (XELOX) Met - Version 2	Inactive
Capecitabine and RT – 7 day - Version 3	Active
Capecitabine and Temozolomide - Version 1	Inactive
Capecitabine Monotherapy Adj - Version 2	Inactive
Capecitabine Monotherapy LA/M - Version 2	Inactive
CARBOplatin (AUC 2) Weekly and PACLitaxel (50mg/m ²) Weekly with Radiotherapy (RT) -5 weeks - Version 5	Active
CARBOplatin (AUC 2) Weekly with Radiotherapy (RT) - Version 3	Active
CARBOplatin (AUC 3), Etoposide (50mg/m ²) and Thoracic Radiotherapy (TRT) -28 day - Version 2	Active
CARBOplatin (AUC 5) and 5-Fluorouracil 1000mg/m ² /day – 28 day - Version 4	Active
CARBOplatin (AUC 6) and PACLitaxel 200mg/m ² - Version 4	Inactive
CARBOplatin (AUC1.5) Chemoradiation - 7 days - Version 3	Inactive
CARBOplatin (AUC5) and Etoposide 100mg/m ² - 21 days - Version 7	Active
CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m ² followed by Dose Dense DOXorubicin Cyclophosphamide Therapy- Triple Negative Breast Cancer - Version 3	Inactive
CARBOplatin and Oral Etoposide - 21days - Version 2	Inactive
CARBOplatin AUC4 Monotherapy-21 days - Version 2	Active

Regimen list

Regimen	Status
CARBOplatin AUC4 Monotherapy-28 days - Version 2	Active
CARBOplatin AUC5 and PACLitaxel 175mg/m ² Adj - Version 1	Inactive
CARBOplatin AUC5 and PACLitaxel 175mg/m ² Met - Version 1	Inactive
CARBOplatin AUC5 Monotherapy-21 days - Version 2	Active
CARBOplatin AUC5 Monotherapy-28 days - Version 2	Active
CARBOplatin AUC6 and PACLitaxel 175mg/m ² Adj - Version 1	Inactive
CARBOplatin AUC6 and PACLitaxel 175mg/m ² Met - Version 1	Inactive
CARBOplatin AUC6 Monotherapy-21 days - Version 4	Active
CARBOplatin AUC6 Monotherapy-28 days - Version 4	Active
CARBOplatin AUC7 and PACLitaxel 175mg/m ² Adj - Version 1	Inactive
CARBOplatin AUC7 and PACLitaxel 175mg/m ² Met - Version 1	Inactive
CARBOplatin AUC7.5 and PACLitaxel 175mg/m ² Adj - Version 4	Inactive
CARBOplatin AUC7.5 and PACLitaxel 175mg/m ² Met - Version 4	Inactive
Carfilzomib, Lenalidomide and Dexamethasone (KRd) - 28 day - Version 3	Active
Cetuximab - 7 day (12 weeks) - Version 3	Inactive
Cetuximab - 7 day (8 weeks) - Version 3	Inactive
Cetuximab (14 days) and FOLFIRI (14 days) - Version 1	Inactive
Cetuximab (14 days) and Irinotecan (14 days) - Version 1	Inactive
Cetuximab (7 days) and FOLFIRI (14 days) Therapy - Version 3	Inactive
Cetuximab (7 days) and Irinotecan (14 days) - Version 1	Inactive
Cetuximab (weekly), CARBOplatin AUC 5 and 5-FU 1000mg/m ² /day - 21 day cycle - Version 6	Inactive
Cetuximab (weekly), CISplatin 100mg/m ² and 5-Fluorouracil 1000mg/m ² /day - 21 day cycle - Version 4	Inactive
Chlorambucil 10mg/m ² - Version 1	Active
CHOEP – 21 days - Version 2	Active
CISplatin (100mg/m ²) with Radiotherapy (RT) - 21 day - Version 4	Active
CISplatin (40mg/m ²) Weekly with Radiotherapy (RT) (5 cycles) - Version 6	Active
CISplatin (40mg/m ²) Weekly with Radiotherapy (RT) (6 cycles) - Version 5	Active
CISplatin (50mg/m ²) and Etoposide (50mg/m ²) and Thoracic Radiotherapy (TRT) -28 day - Version 4	Active
CISplatin (75mg/m ²) + Etoposide - 21 day - Version 2	Inactive
CISplatin (75mg/m ²) + Etoposide (100mg/m ²) +Thoracic Radiotherapy (TRT) -21 day - Version 2	Inactive
CISplatin 75mg/m ² and 5-Fluorouracil Chemoradiation - Herskovic Regimen - Version 3	Inactive
CISplatin and 5-Fluorouracil- 28 day cycle - Version 1	Inactive
CISplatin and Capecitabine Adjuvant Chemoradiation - Version 1	Inactive
CISplatin, Methotrexate and vinBLASTine (CMV) - Version 1	Inactive
Cladribine 0.14mg/kg Day 1 to 5 Therapy - Version 1	Active
Cladribine 0.14mg/kg Weekly - Version 1	Active
Cladribine 5 day and riTUXimab - Version 1	Inactive
Cladribine Weekly and riTUXimab - Version 1	Inactive
Crizotinib Monotherapy - Version 3	Active
Cyclophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 21 Day Adj - Version 2	Inactive
Cyclophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 21 Day Met - Version 2	Inactive
Cyclophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 28 day Adj - Version 1	Inactive
Cyclophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 28 Day Met - Version 1	Inactive
Cyclophosphamide (Oral) Methotrexate and 5-Fluorouracil (CMF) Met - Version 1	Inactive
Cyclophosphamide(Oral) Methotrexate and 5-Fluorouracil (CMF) Adj - Version 1	Inactive
Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) 21-Day - Version 2	Active
DA (50/100) (3+8) Course 2 Induction (AML-17) - Version 1	Inactive
DA(60/100) 3+10: Course 1 Induction (AML-17) - Version 2	Inactive
Dabrafenib Monotherapy - Version 2	Active
Dacarbazine (1.2g/m ²) -21 day - Version 1	Inactive

Regimen list

Regimen	Status
DACTINomycin - Version 1	Active
Daratumumab Monotherapy - Version 2	Inactive
Decitabine Monotherapy - Version 1	Inactive
Degarelix-28 day - Version 1	Inactive
Dexamethasone, riTUXimab and Cyclophosphamide (DRC) - Version 1	Inactive
Docetaxel /Cyclophosphamide (TC)-21 day - Version 3	Inactive
DOCEtaxel 75mg/m ² –Prednisolone Combination - Version 1	Active
DOCEtaxel Monotherapy 100mg/m ² - 21 day - Version 2	Active
DOCEtaxel Monotherapy 50mg/m ² – 14 day cycle - Version 3	Inactive
Docetaxel Monotherapy 75mg/m ² – 21 day cycle - Version 1	Active
DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days - Version 5	Inactive
DOCEtaxel, CISplatin and 5-Fluorouracil Chemoradiation (Induction) Therapy - Version 1	Inactive
DOCEtaxel,CISplatin, 5-Fluorouracil and Radiotherapy - Version 1	Inactive
Dose Adjusted R-EPOCH - Version 3	Active
Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day (DD AC-T) - Version 5	Active
Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH) - Version 1	Inactive
Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (80) 7 day (DD AC-T) - Version 4	Inactive
Dose Dense DOXOrubicin, Cyclophosphamide (AC60/600) 14 day followed by weekly PACLitaxel and Trastuzumab Therapy (DD AC-TH) - Version 2	Inactive
DOXOrubicin (25mg/m ² /day) and CISplatin (100mg/m ²)-21 day cycle - Version 1	Inactive
DOXOrubicin (60) and Ifosfamide - Version 1	Inactive
DOXOrubicin (60mg/m ²) - Version 3	Active
DOXOrubicin (75) and Ifosfamide - Version 2	Inactive
DOXOrubicin 50mg/m ² /Docetaxel 75mg/m ² (AT 50/75)-21 day cycle - Version 1	Inactive
DOXOrubicin 75mg/m ² Monotherapy - Version 1	Inactive
DOXOrubicin, and Cyclophosphamide (AC 60/600) - 21 day - Version 1	Inactive
DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab (AC-TH) - Version 1	Inactive
DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) - Version 2	Inactive
EMA/CO Therapy (Etoposide, Methotrexate, DACTINomycin, Cyclophosphamide, vinCRISline) - Version 1	Active
Encorafenib and Binimetinib - Version 1	Inactive
Enzalutamide Monotherapy - Version 2	Inactive
EP/EMA Therapy (Etoposide CISplatin/Etoposide Methotrexate DACTINomycin) - Version 1	Inactive
Epirubicin 75 + Cyclophosphamide (EC75) -21 day - Version 1	Inactive
Epirubicin 90 + Cyclophosphamide (EC90)-21 day - Version 1	Inactive
EpiRUBicin, CISplatin and 5-Fluorouracil (ECF) - ADJ -21 day - Version 1	Inactive
EpiRUBicin, CISplatin and 5-Fluorouracil (ECF) -21 day LA/M - Version 1	Inactive
EpiRUBicin, Oxaliplatin and 5-Fluorouracil (EOF)- 21 day - Version 1	Inactive
Epirubicin, Oxaliplatin and Capecitabine (EOX) -21 day - Version 2	Inactive
EriBULin Monotherapy - Version 2	Active
Erlotinib Monotherapy - Version 2	Active
Escalated Dose BEACOPP 21 day - Version 2	Inactive
Etoposide and CISplatin 20mg/m ² (EP) 5 day - Version 2	Inactive
Everolimus and Exemestane - Version 1	Inactive
Everolimus Monotherapy - Version 1	Active
Exemestane Monotherapy Adj - Version 1	Active
Exemestane Monotherapy Met - Version 1	Active
FLAG: Ida 8mg/m ² - Version 3	Active
FLOT -14 day NAdj - Version 3	Active
FLOT-14 day Adj - Version 3	Active
Fludarabine, cyclophosphamide and riTUXimab (FC IV+R) - Version 3	Active
Fludarabine, cyclophosphamide and riTUXimab (FC Oral +R) - Version 1	Active

Regimen list

Regimen	Status
FOLFIRI 14 day - Version 3	Inactive
FOLFIRINOX - Version 1	Inactive
FOLFOX-4 14 day Adj - Version 4	Inactive
FOLFOX-4 14 day Met - Version 2	Inactive
FOLFOXIRI - Version 1	Inactive
Fulvestrant - Version 1	Active
Gemcitabine (1000mg/m ²) and RT - Version 2	Active
Gemcitabine (1000mg/m ²) and CARBOplatin (AUC 4) - 21 day - Version 3	Inactive
Gemcitabine (1000mg/m ²) and CARBOplatin (AUC 5)- 21 day - Version 2	Inactive
Gemcitabine (1000mg/m ²) and CISplatin (70mg/m ²) Therapy- 28 day - Version 1	Inactive
Gemcitabine (1000mg/m ²) Monotherapy - 28 day Adj - Version 3	Active
Gemcitabine (1000mg/m ²) Monotherapy - 28 day Met - Version 3	Active
Gemcitabine (1000mg/m ²) Monotherapy - 56 day - Version 2	Inactive
Gemcitabine (1000mg/m ²), CARBOplatin (AUC 4) and Bevacizumab 15mg/kg - 21 day - Version 2	Inactive
Gemcitabine (1250mg/m ²) and CISplatin (75mg/m ²)- 21 day - Version 1	Inactive
Gemcitabine (1250mg/m ²) and CISplatin (80mg/m ²) - 21 day - Version 1	Inactive
Gemcitabine (1250mg/m ²) Monotherapy - 21 day - Version 1	Active
Gemcitabine (400mg/m ²) and RT - Version 2	Active
Gemcitabine (600mg/m ²) and RT-7 day - Version 1	Active
Gemcitabine and CARBOplatin (AUC2) - 21 days - Version 1	Inactive
Gemcitabine and DOCEtaxel - 21 day - Version 1	Inactive
Goserelin 10.8mg-12 weeks - Version 1	Inactive
High Dose Cytarabine - Version 2	Inactive
High Dose Melphalan Conditioning for Autologous Stem Cell Transplant - Version 1	Active
Ibrutinib Therapy CLL / Waldenström's macroglobulinaemia - Version 1	Active
Ibrutinib Therapy Mantle Cell Lymphoma - Version 1	Active
Idelalisib Monotherapy - Version 1	Active
Imatinib - GIST Adj - Version 1	Inactive
Imatinib - GIST Met - Version 1	Inactive
Intermediate Dose Cytarabine - Version 3	Inactive
Intrathecal Methotrexate for CNS prophylaxis in GTN - Version 1	Active
Intravenous Vinorelbine Monotherapy - 21 day - Version 1	Inactive
Ipilimumab Monotherapy - Version 2	Inactive
Irinotecan Monotherapy - 21 days - Version 2	Active
LEAM Autologous Transplant Conditioning - Version 3	Inactive
Lenvatinib -DTC Therapy - Version 2	Active
Letrozole Monotherapy Adj - Version 3	Active
Letrozole Monotherapy Met - Version 3	Active
Letrozole Monotherapy NAdj - Version 2	Active
Leuprorelin 11.25mg-12 weeks - Version 1	Inactive
Leuprorelin 22.5mg-12 weeks - Version 1	Inactive
Leuprorelin 45mg-24 week - Version 1	Inactive
Methotrexate 8 day Charing Cross Regimen - Version 1	Active
Methotrexate,vinBLASTine, DOXOrubicin, CISplatin (MVAC) -14 Days - Version 1	Inactive
Methotrexate,vinBLASTine, DOXOrubicin, CISplatin (MVAC) -28 Days Adj - Version 1	Inactive
Methotrexate,vinBLASTine, DOXOrubicin, CISplatin (MVAC) -28 Days Met - Version 1	Inactive
Methotrexate,vinBLASTine, DOXOrubicin, CISplatin (MVAC) -28 Days NAdj - Version 1	Inactive
Mifamurtide - Version 1	Inactive
Modified CyBorD/ Bortezomib, Cylophosphamide and Dexamethasone – Weekly Therapy - Version 2	Active
Modified FOLFOX-6 14 day Adj - Version 6	Active
Modified FOLFOX-6 14 day Met - Version 5	Active
Modified FOLFOX-6 Chemoradiation-14 day - Version 1	Inactive
Modified Roswell Park (Fluorouracil 500mg/m ² and Folinic Acid 50mg weekly x 6) Regimen Adj - Version 1	Inactive

Regimen list

Regimen	Status
Modified Roswell Park (Fluorouracil 500mg/m ² and Folinic Acid 50mg weekly x 6) Regimen Met - Version 1	Inactive
Nab-Paclitaxel (Abraxane) and Gemcitabine - 28 day - Version 2	Inactive
Nab-PACLitaxel (Abraxane®) Monotherapy- 21 day - Version 1	Inactive
Neoadjuvant DOCEtaxel, CISplatin,5-Fluorouracil and Chemoradiation and Surgery - Version 2	Inactive
Nivolumab 1mg/kg Ipilimumab 3mg/kg - Version 1	Inactive
Nivolumab 3mg/kg with Ipilimumab 1mg/kg - Version 1	Inactive
Nivolumab Monotherapy 240mg - 14 days (6 cycles) - Version 3	Active
Nivolumab Monotherapy 240mg - 14 days Adj (26 cycles) - Version 2	Active
Nivolumab Monotherapy 480mg-28 days (3 cycles) - Version 2	Active
Nivolumab Monotherapy 480mg-28 days Adj (13 cycles) - Version 2	Active
Obinutuzumab and Bendamustine-28 day cycle - Version 1	Active
Obinutuzumab and Chlorambucil - Version 1	Inactive
Obinutuzumab and CHOP-21 day - Version 1	Inactive
Obinutuzumab Cyclophosphamide vinCRISTine and prednisoLONE (O-CVP)-21 days - Version 2	Inactive
Obinutuzumab Maintenance Therapy-56 day - Version 1	Active
Olaparib (Capsule) Monotherapy - Version 1	Active
Oral Etoposide - Version 2	Active
Oral Vinorelbine Monotherapy-7 days - Version 2	Inactive
PACLitaxel (80) and Trastuzumab-7 day (12 weeks) - Version 2	Active
PACLitaxel Monotherapy 80mg/m ² - Version 4	Inactive
PACLitaxel/CISplatin alternating with PACLitaxel/Etoposide (TP/TE) - Version 1	Inactive
Palbociclib-28 day - Version 2	Active
Panitumumab 6mg/kg - Version 2	Active
Panitumumab 6mg/kg and FOLFIRI -14 day - Version 2	Inactive
Panitumumab 6mg/kg and Modified FOLFOX-6 – 14 day - Version 1	Inactive
Pegylated Liposomal DOXOrubicin 20 mg/m ² (CAELYX)® 21 days - Version 2	Active
Pegylated Liposomal Doxorubicin 50mg/m ² (CAELYX) 28 days - Version 2	Inactive
Pembrolizumab 200mg Monotherapy - Version 1	Inactive
Pembrolizumab 400mg Monotherapy - Version 1	Inactive
Pembrolizumab, PACLitaxel and CARBOplatin (AUC 6) - Version 1	Inactive
Pembrolizumab, PEMEtrexed and CARBOplatin (AUC 5) - Version 1	Inactive
PEMEtrexed and CARBOplatin - Version 2	Inactive
PEMEtrexed and CISplatin - Version 1	Inactive
PEMEtrexed Monotherapy - Version 1	Inactive
Pertuzumab and Trastuzumab and DOCEtaxel Therapy - 21 day - Version 2	Active
Pertuzumab Trastuzumab and Vinorelbine - Version 1	Active
Pertuzumab Trastuzumab and Weekly PACLitaxel - 21 day cycle - Version 2	Inactive
Pixantrone - Version 1	Inactive
Pomalidomide and Dexamethasone - Version 1	Inactive
Procarbazine Lomustine and VinCRISTine (PCV) - Version 2	Inactive
QUASAR (Modified) Fluorouracil (370mg/m ²) and Folinic Acid (50mg) Weekly Adj - Version 4	Inactive
QUASAR (Modified) Fluorouracil (370mg/m ²) and Folinic Acid (50mg) Weekly Met - Version 3	Inactive
R- miniCHOP - 21 days - Version 2	Active
R-CEOP – 21 days - Version 1	Active
R-CHOP - 21 days - Version 4	Active
R-CHOP-14 days - Version 4	Active
R-CODOX-M (Patients >65 years) - Version 1	Inactive
R-CODOX-M (Patients ≤65yrs) - Version 1	Inactive
R-CVP – 21 days riTUXimab, Cyclophosphamide vinCRISTine and Prednisolone - Version 2	Active
R-DHAP - Version 1	Active
Regorafenib Monotherapy - Version 2	Active

Regimen list

Regimen	Status
R-ESHAP - Version 1	Inactive
R-Gemcitabine (1000mg/m ²) Oxaliplatin - 14 day - Version 1	Inactive
R-ICE (RiTUXimab), Ifosfamide, Carboplatin and Etoposide) - Version 1	Inactive
RiTUXimab 375 mg/m ² - 7 day - Version 1	Active
riTUXimab 375 mg/m ² Combination Therapy-21 day - Version 1	Active
RiTUXimab 375 mg/m ² Maintenance Therapy- 56 day - Version 1	Active
RiTUXimab 375mg/m ² - Follicular Lymphoma (every 2 months) - Version 2	Inactive
RiTUXimab 375mg/m ² - Follicular Lymphoma (every 3 months) - Version 2	Inactive
RiTUXimab 375mg/m ² - Follicular Lymphoma (once weekly for four weeks) - Version 2	Inactive
RiTUXimab 375mg/m ² Maintenance-84 day - Version 1	Active
RiTUXimab and Bendamustine - Version 2	Active
riTUXimab** Gemcitabine, Dexamethasone and Cisplatin ((R**)-GDP) - Version 1	Active
Ruxolitinib Monotherapy - Version 1	Inactive
SORafenib - Version 1	Inactive
Tamoxifen Monotherapy Adj - Version 1	Inactive
Tamoxifen Monotherapy Met - Version 1	Inactive
Temozolomide Recurrent Therapy - Version 1	Inactive
Temozolomide with Radiotherapy (RT) and Adjuvant Therapy - Version 1	Inactive
Temozolomide with Radiotherapy (RT) and Adjuvant Therapy - Patients greater than 65 years - Version 1	Inactive
Temsirolimus Monotherapy - Version 2	Active
Topotecan Monotherapy – 5 day - Version 2	Inactive
Topotecan Monotherapy – Weekly - Version 2	Inactive
Topotecan Oral Monotherapy - Version 1	Inactive
Trametinib and Dabrafenib - Version 1	Inactive
Trastuzumab (IV) Monotherapy - 21 days Adj - Version 2	Active
Trastuzumab (IV) Monotherapy - 7 days - Version 1	Inactive
Trastuzumab (IV) Monotherapy- 21 days Met - Version 2	Active
Trastuzumab 5-Fluorouracil and Cisplatin - 21 days - Version 3	Active
Trastuzumab Emtansine (Kadcyla®) - 21 days - Version 2	Active
Trastuzumab Subcutaneous 21 days - Metastatic Breast Cancer - Version 3	Active
Trastuzumab Subcutaneous 21 days - Early Breast Cancer - Version 3	Active
Tretinoin (ATRA) with Arsenic Trioxide (ATO) Consolidation - Version 1	Inactive
Tretinoin (ATRA) with Arsenic Trioxide (ATO) Induction - Version 1	Inactive
Two Day Etoposide Cisplatin (EP) - Version 1	Inactive
Vandetanib Therapy - Version 1	Active
Vemurafenib Monotherapy - Version 2	Inactive
Venetoclax Monotherapy - Version 1	Active
VinBLAStine and Methotrexate - Version 1	Active
Vinorelbine 30 (Day 1,8,15) and Cisplatin 80 (Day1) Therapy- 21 day - Version 1	Inactive
Vismodegib Monotherapy - Version 2	Active
Weekly CARBOplatin (AUC2) PACLitaxel 50mg/m ² with Radiotherapy - Version 5	Active
Zoledronic Acid Monotherapy - Version 1	Active